Almost 50 years after the discovery of rifampin, clinicians and tuberculosis programmes finally have treatment options to offer people with rifampin-resistant tuberculosis, which can improve outcomes and limit toxic effects associated with conventional treatment. Such innovations include the newer drugs bedaquiline and delamanid, repurposed drugs such as linezolid or clofazimine, and shorter regimens.¹ Because of limited availability and resources, many programmes, policy makers, and clinicians have had to choose between using bedaquiline or delamanid, but not both.

中文翻译：

---

贝达喹啉或德拉马尼治疗利福平耐药结核病？

利福平发现近 50 年后，临床医生和结核病项目终于有了为利福平耐药结核病患者提供治疗选择的方法，这可以改善结果并限制与常规治疗相关的毒性作用。此类创新包括更新的药物贝达喹啉和德拉马尼、利奈唑胺或氯法齐明等重新利用的药物以及更短的治疗方案。¹由于可用性和资源有限，许多项目、政策制定者和临床医生不得不在使用贝达喹啉或德拉马尼之间做出选择，但不能同时使用两者。